Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: This phase II trial is studying how well atrasentan works in treating patients with
locally recurrent or metastatic kidney cancer.